Servier Continues Oncology Winning Streak With Tibsovo Approval For MDS
The targeted therapy won approval for myelodysplastic syndrome patients with IDH1 mutations, who have a higher propensity for progression to acute myeloid leukemia.
The targeted therapy won approval for myelodysplastic syndrome patients with IDH1 mutations, who have a higher propensity for progression to acute myeloid leukemia.